EUCTR2005-002003-17-SE进行中（未招募）不适用
High-dose therapy with autologous stem cell support in first line treatment of mantle cell lymphoma - Yttrium-90-ibritutomab tiutexan in combination with BEAM or BEAC to improve outcome for patients not in CR after induction treatment. - Nordic mantle cell lymphoma protocol III
ppsala University Hospital0 个研究点目标入组 150 人开始时间: 2005年12月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically and immunohistochemically defined diagnos of mantle cell lymphoma.
- •Previously untreated, except one course of any ´regimen.
- •18-65 years of age.
- •WHO performance status 0-3.
- •Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Previously treated for lymphoma.
- •Severe medical conditions or infections.
- •History of other malignancies.
- •Severe psychiatric disorders.
- •Unwilling or unable to comply with the protocol.
研究者
相似试验
进行中（未招募）
1 期
High-dose therapy with autologous stem cell support in first line treatment of mantle cell lymphoma - Yttrium-90-ibritumomab tiuxetan in combination with BEAM or BEAC to improve outcome for patients not in CR after induction treatment. - 3. Mantle cell lymphoma phase II protocolMantle cell lymphoma is a non-Hodgkin lymphoma which is rare and holds a bad prognosis with no known curative therapies available. The lymphoma is most often disseminated at diagnosis.EUCTR2005-002003-17-DKRikshospitalet-Radiumhospitalet HF150
进行中（未招募）
1 期
High-dose therapy with autologous stem cell support in first line treatment of mantle cell lymphoma - Yttrium-90-ibritumomab tiuxetan in combination with BEAM or BEAC to improve outcome for patients not in CR after induction treatment. - 3. Mantle cell lymphoma phase II protocolEUCTR2005-002003-17-NORikshospitalet-Radiumhospitalet HF150
进行中（未招募）
不适用
High-dose therapy with autologous stem cell support in first line treatment of mantle cell lymphoma - Yttrium-90-ibritumomab tiuxetan in combination with BEAM or BEAC to improve outcome for patients not in CR after induction treatment. - 3. Mantle cell lymphoma phase II protocolMantle cell lymphoma is a non-Hodgkin lymphoma which is rare and holds a bad prognosis with no known curative therapies available. The lymphoma is most often disseminated at diagnosis.EUCTR2005-002003-17-FIRikshospitalet-Radiumhospitalet HF150
进行中（未招募）
1 期
High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma -randomized phase III trialPrimary CNS lymphoma (PCNSL) accounts for 1 to 2% of all Non-Hodgkin's lymphomas (NHL) and for 2 to 7% of all primary CNS tumors.It's incidence has increased over the past 30 years, particularly in immunocompetent individuals. Over 90% of PCNSL are lymphomas of Bcell origin, accounting to the subtype diffuse large B-cell lymphoma.(DLBCL). Prognosis without treatment resembles that of systemic highgrade NHL, and the median survival of untreated patients with PCNSL is approximately 3 months.MedDRA version: 21.0Level: PTClassification code 10007953Term: Central nervous system lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000620-17-ITCITY OF STUTTGART, REPRESENTED BY KLINIKUM STUTTGART250
进行中（未招募）
1 期
In the presently planned multicentre Phase III trial the two therapies will be compared: Patients will be randomized after intensified induction treatment with 4 cycles rituximab, methotrexate, cytarabine and thiotepa (MATRix) between first-line high-dose chemotherapy against conventional consolidating therapy with 2 cycles of conventional chemotherapy with R-DeVIC (Rituximab, Dexamthason, Etoposide, Ifosfamide, Carboplatin).Primary CNS lymphoma (PCNSL) accounts for 1 to 2% of all Non-Hodgkin's lymphomas (NHL) and for 2 to 7% of all primary CNS tumors. It's incidence has increased over the past 30 years, particularly in immunocompetent individuals. Over 90% of PCNSL are lymphomas of B-cell origin, accounting to the subtype diffuse large B-cell lymphoma. (DLBCL). Prognosis without treatment resembles that of systemic high-grade NHL, and the median survival of untreated patients with PCNSL is approximately 3 months.EUCTR2012-000620-17-DEandeshauptstadt Stuttgart, represented by the Executive Medical Director Klinikum Stuttgart330